GSK plc (LON:GSK)
London flag London · Delayed Price · Currency is GBP · Price in GBX
1,488.50
+11.00 (0.74%)
Mar 28, 2025, 5:34 PM BST

GSK plc Company Description

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines.

It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson’s disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.

The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

GSK plc
GSK plc logo
Country United Kingdom
Founded 1715
Industry Drug Manufacturers - General
Sector Healthcare
Employees 68,629
CEO Emma Walmsley

Contact Details

Address:
79 New Oxford Street
England, WC1A 1DG
United Kingdom
Phone 44 20 8047 5000
Website gsk.com

Stock Details

Ticker Symbol GSK
Exchange London Stock Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency GBP
ISIN Number GB00BN7SWP63
SIC Code 2834

Key Executives

Name Position
Sally Jackson Senior Vice President of Global Communications and Chief Executive Officer Office
Emma Natasha Walmsley Chief Executive Officer and Director
Julie Belita Brown A.C.A. Chief Financial Officer and Executive Director
Shobie Ramakrishnan Chief Digital and Technology Officer
Tony Wood Chief Scientific Officer and Head of Research & Development
James Ford Senior Vice President and Group General Counsel of Legal & Compliance
David Simon Redfern BSc (Hons), CA President of Corporate Development
Diana Conrad Chief People Officer
Philip C. Thomson President of Global Affairs
Luke V. Miels Chief Commercial Officer